TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Yesterday

NL

Article

TMFBiologyFool published an article 3:44 AM

Sarepta's Roller Coaster Hits a High Point

Let's hope Sarepta Therapeutics doesn't follow in Prosensa and GlaxoSmithKline's footsteps and come crashing down.

Mon Apr 21

NL

Article

TMFBiologyFool published an article 7:53 PM

Biotech Earnings Preview

A rundown of what to expect from Gilead Sciences, Arena Pharmaceuticals, and Biogen Idec.

NL

Article

TMFBiologyFool published an article 7:44 PM

A Doozy of a Pharma Rumor

Pfizer was reportedly interested in buying AstraZeneca taking us back to an era of mega-mergers such as Pfizer-Wyeth and Merck-Schering-Plough.

Sat Apr 19

NL

Article

TMFBiologyFool published an article 1:30 PM

This Medical Marijuana Stock Is Not What You Think

GW Pharmaceuticals is more like Biogen, Teva Pharmaceuticals, and Acorda Therapeutics than penny-stock companies hocking medical marijuana.

Thu Apr 17

NL

Article

TMFBiologyFool published an article 2:56 PM

3 Reasons the Market Is Down on Gilead Sciences

Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.

Mon Apr 14

NL

Article

TMFBiologyFool published an article 7:37 PM

Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)

The market cap of Galena Biopharma, Sangamo BioSciences, and ANI Pharmaceuticals, and MannKind is more important than the share price.

NL

Article

TMFBiologyFool published an article 5:50 PM

Amgen's Conundrum

What will Amgen do with T-VEC and will it be able to compete with Bristol-Myers Squibb's Yervoy, which is already on the market, and Merck's (NYSE: MRK) experimental anti-PD-1 antibody MK-3475.

NL

Article

TMFBiologyFool published an article 5:37 PM

MannKind's Overly-Optimisitic Investors

Despite issues, over half of investors in a Motley Fool poll thought MannKind's inhaled insulin, Afrezza, would be approved this week.

NL

Article

TMFBiologyFool published an article 5:25 PM

Biotech Tweet of the Week: Love Being Private

Investors often ignore private biotechs because they can't buy shares, but investors in companies such as InterMune and the obesity drug makers -- Arena Pharmaceuticals, VIVUS, and Orexigen -- need to follow their privately-held competitors.

Mon Apr 7

NL

Article

TMFBiologyFool published an article 7:56 PM

Biotech of the Week: Agios Pharmaceuticals

Agios Pharmaceuticals presents promising data on AG-221, which is partnered with Celgene.

NL

Article

TMFBiologyFool published an article 4:19 PM

A $1 Trillion Drug Market?

That's what Arrowhead Research claims, but it should look at Gilead Sciences pricing in developing markets before spouting such inflated numbers.

Wed Apr 2

NL

Article

TMFBiologyFool published an article 3:40 PM

Positive Panel, but 3 Risks Remain for MannKind Corporation

The FDA advisory committee overwhelmingly recommends approving MannKind's Afrezza.

Article Comment

TMFBiologyFool commented on an article. 2:06 AM

Talk About High Clinical Trial Expectations

@VitamanD You're right that survival in patients that have failed other treatments should be shorter, but Exelixis based the number of patients needed on the expected survival (among other things).

My point is

[more]

Mon Mar 31

NL

Article

TMFBiologyFool published an article 7:30 PM

Exelixis Continues On

Exelixis' shares got hammered after announing that it was continuing a clinical trial testing Cometriq in prostate cancer. Investors seem to be worried about how well Cometriq might compete with drugs from Johnson & Johnson and Medivation, assuming [more]

NL

Article

TMFBiologyFool published an article 6:56 PM

Can Arena and VIVUS Profit From Glaxo's Troubles?

GlaxoSmithKline had to recall its obesity drug alli, but it isn't clear if Arena Pharmaceuticals and VIVUS will be able to benefit.

NL

Article

TMFBiologyFool published an article 5:40 PM

Biotechs Giving Uncle Sam the Shaft

Horizon Pharma, Actavis, Alkermes, and Perrigo have all purchased companies in part to move out of the U.S. and lower their tax rates. The strategy could make companies such as Jazz Pharmaceuticals a takeout target.

NL

Article

TMFBiologyFool published an article 4:33 PM

Is This a Biotech Dip, Correction, or Time to Panic?

Biotech has fallen on potential pricing pressure for hepatitis C drugs from Gilead Sciences and AbbVie, but there may be more to the sell-off, providing a buying opportunity for some high flyers, such as Regeneron Pharmaceuticals.

NL

Article

TMFBiologyFool published an article 2:40 PM

MannKind Fails to Learn From Its Mistake

Changing products between clinical trials and submission is never a good idea.

Fri Mar 28

NL

Article

TMFBiologyFool published an article 12:39 PM

Finding a Niche for Celgene's Otezla

Celgene's Otezla isn't going to beat antiinflamatory drugs from AbbVie, Johnson & Johnson, and Amgen on efficacy, but the biotech can still find a niche for its new psoriatic arthritis drug.

Thu Mar 27

NL

Article

TMFBiologyFool published an article 10:08 PM

MannKind's Upcoming Catalyst(s)

MannKind's Afrezza faces an advisory committee meeting. If approved, the inhaled insulin will have to compete with injected versions made by Eli Lilly and Novo Nordisk.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 98.63
Player Rank 1025 out of 74858
Score 2275.65
Score Change Today +1.05
Accuracy 67.63%
Active Picks 77
Total Picks 212
Best Pick MYL (+268.86)
Worst Pick INCY (-373.22)
Average Score per Pick 10.73
Charms Earned 9
Highest Rated Favorite TMFCandyMountain
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts